Almirall Knocked Back By US Woes, Could Affect Other Companies Too
Spain’s Almirall has suffered business setbacks in the US - including in its patient assistance program - that have forced the mid-sized drug maker to issue a profit warning, triggering of a sharp slide in its share price.
You may also be interested in...
Peter Guenter has steadied the ship at Almirall, and after seven months in the role he outlines his vision for the company in his first exclusive interview as CEO of Spain's largest pharma company.
The Spanish company has a lot riding on tildrakizumab, the psoriasis drug licensed from Sun Pharma which could get the green light in Europe before year-end. Until then, Almirall is scouring the market for bolt-on deals.
Peter Guenter, brought in from Sanofi to fix the problems at Almirall, is staying focused on 2018 as he outlines his plan to rebuild the Spanish company. Almirall will continue reallocating resources and seeking bolt-on deals to establish a sustainable dermatology business as it rolls out Skilarence and tildrakizumab in Europe.